Comparative study between virus neutralisation testing and other serological methods detecting anti-SARS-CoV-2 antibodies in Europe, 2021
Аутори
Mögling, RamonaReimerink, Johan
Stanoeva, Kamelia R.
Keramarou, Maria
Guiomar, Raquel
Costa, Inês
Haveri, Anu
Holzer, Barbara
Korukluoğlu, Gülay
Nguyen, Trung
Pakarna, Gatis
Pancer, Katarzyna
Trilar, Katarina Prosenc
Protić, Jelena
Stojanović, Marijana
De Santis, Riccardo
Lista, Florigio
Vremera, Teodora
Leustean, Mihaela
Pistol, Adriana
Zelena, Hana
Reusken, Chantal
Broberg, Eeva K.
Чланак у часопису (Објављена верзија)
Метаподаци
Приказ свих података о документуАпстракт
One consequence of the ongoing coronavirus disease pandemic was the rapid development of both in-house and commercial serological assays detecting anti-SARS-CoV-2 antibodies, in an effort to reliably detect acute and past SARS-CoV-2 infections. It is crucial to evaluate the quality of these serological tests and consequently the sero-epidemiological studies that are performed with the respective tests. Here, we describe the set-up and results of a comparative study, in which a laboratory contracted by the European Centre for Disease Prevention and Control offered a centralised service to EU/EEA Member and pre-accession Member States to test representative serum specimens with known serological results, with the gold standard technique (virus neutralisation tests) to determine the presence of neutralising antibodies. Laboratories from 12 European countries shared 719 serum specimens with the contractor laboratory. We found that in-house serological tests detecting neutralising antibodie...s showed the highest percent agreement, both positive and negative, with the virus neutralisation test results. Despite extensive differences in virus neutralisation protocols neutralisation titres showed a strong correlation. From the commercial assays, the best positive percent agreement was found for SARS-CoV-2 IgG (sCOVG) (Siemens - Atellica IM Analyzer). Despite lower positive percent agreement of LIAISON SARS-CoV-2 TrimericS IgG kit (Diasorin Inc.), the obtained results showed relatively good correlation with neutralisation titres. The set-up of this study allowed for high comparability between laboratories and enabled laboratories that do not have the capacity or capability to perform VNTs themselves. Given the variety of in-house protocols detecting SARS-CoV-2 specific neutralising antibodies, including the virus strain, it could be of interest to select reference isolates for SARS-CoV-2 diagnostic to be made available for interested EU Member States and pre-accession countries.
Кључне речи:
COVID-19 / Europe / SARS-CoV-2 / Serology / Virus neutralisationИзвор:
Journal of Virological Methods, 2023, 322, 114825-Издавач:
- Elsevier
Финансирање / пројекти:
- European Centre for Disease Prevention and Control (ECDC) under direct contract No ECD.11508
Институција/група
TorlakTY - JOUR AU - Mögling, Ramona AU - Reimerink, Johan AU - Stanoeva, Kamelia R. AU - Keramarou, Maria AU - Guiomar, Raquel AU - Costa, Inês AU - Haveri, Anu AU - Holzer, Barbara AU - Korukluoğlu, Gülay AU - Nguyen, Trung AU - Pakarna, Gatis AU - Pancer, Katarzyna AU - Trilar, Katarina Prosenc AU - Protić, Jelena AU - Stojanović, Marijana AU - De Santis, Riccardo AU - Lista, Florigio AU - Vremera, Teodora AU - Leustean, Mihaela AU - Pistol, Adriana AU - Zelena, Hana AU - Reusken, Chantal AU - Broberg, Eeva K. PY - 2023 UR - http://intor.torlakinstitut.com/handle/123456789/805 AB - One consequence of the ongoing coronavirus disease pandemic was the rapid development of both in-house and commercial serological assays detecting anti-SARS-CoV-2 antibodies, in an effort to reliably detect acute and past SARS-CoV-2 infections. It is crucial to evaluate the quality of these serological tests and consequently the sero-epidemiological studies that are performed with the respective tests. Here, we describe the set-up and results of a comparative study, in which a laboratory contracted by the European Centre for Disease Prevention and Control offered a centralised service to EU/EEA Member and pre-accession Member States to test representative serum specimens with known serological results, with the gold standard technique (virus neutralisation tests) to determine the presence of neutralising antibodies. Laboratories from 12 European countries shared 719 serum specimens with the contractor laboratory. We found that in-house serological tests detecting neutralising antibodies showed the highest percent agreement, both positive and negative, with the virus neutralisation test results. Despite extensive differences in virus neutralisation protocols neutralisation titres showed a strong correlation. From the commercial assays, the best positive percent agreement was found for SARS-CoV-2 IgG (sCOVG) (Siemens - Atellica IM Analyzer). Despite lower positive percent agreement of LIAISON SARS-CoV-2 TrimericS IgG kit (Diasorin Inc.), the obtained results showed relatively good correlation with neutralisation titres. The set-up of this study allowed for high comparability between laboratories and enabled laboratories that do not have the capacity or capability to perform VNTs themselves. Given the variety of in-house protocols detecting SARS-CoV-2 specific neutralising antibodies, including the virus strain, it could be of interest to select reference isolates for SARS-CoV-2 diagnostic to be made available for interested EU Member States and pre-accession countries. PB - Elsevier T2 - Journal of Virological Methods T1 - Comparative study between virus neutralisation testing and other serological methods detecting anti-SARS-CoV-2 antibodies in Europe, 2021 SP - 114825 VL - 322 DO - 10.1016/j.jviromet.2023.114825 ER -
@article{ author = "Mögling, Ramona and Reimerink, Johan and Stanoeva, Kamelia R. and Keramarou, Maria and Guiomar, Raquel and Costa, Inês and Haveri, Anu and Holzer, Barbara and Korukluoğlu, Gülay and Nguyen, Trung and Pakarna, Gatis and Pancer, Katarzyna and Trilar, Katarina Prosenc and Protić, Jelena and Stojanović, Marijana and De Santis, Riccardo and Lista, Florigio and Vremera, Teodora and Leustean, Mihaela and Pistol, Adriana and Zelena, Hana and Reusken, Chantal and Broberg, Eeva K.", year = "2023", abstract = "One consequence of the ongoing coronavirus disease pandemic was the rapid development of both in-house and commercial serological assays detecting anti-SARS-CoV-2 antibodies, in an effort to reliably detect acute and past SARS-CoV-2 infections. It is crucial to evaluate the quality of these serological tests and consequently the sero-epidemiological studies that are performed with the respective tests. Here, we describe the set-up and results of a comparative study, in which a laboratory contracted by the European Centre for Disease Prevention and Control offered a centralised service to EU/EEA Member and pre-accession Member States to test representative serum specimens with known serological results, with the gold standard technique (virus neutralisation tests) to determine the presence of neutralising antibodies. Laboratories from 12 European countries shared 719 serum specimens with the contractor laboratory. We found that in-house serological tests detecting neutralising antibodies showed the highest percent agreement, both positive and negative, with the virus neutralisation test results. Despite extensive differences in virus neutralisation protocols neutralisation titres showed a strong correlation. From the commercial assays, the best positive percent agreement was found for SARS-CoV-2 IgG (sCOVG) (Siemens - Atellica IM Analyzer). Despite lower positive percent agreement of LIAISON SARS-CoV-2 TrimericS IgG kit (Diasorin Inc.), the obtained results showed relatively good correlation with neutralisation titres. The set-up of this study allowed for high comparability between laboratories and enabled laboratories that do not have the capacity or capability to perform VNTs themselves. Given the variety of in-house protocols detecting SARS-CoV-2 specific neutralising antibodies, including the virus strain, it could be of interest to select reference isolates for SARS-CoV-2 diagnostic to be made available for interested EU Member States and pre-accession countries.", publisher = "Elsevier", journal = "Journal of Virological Methods", title = "Comparative study between virus neutralisation testing and other serological methods detecting anti-SARS-CoV-2 antibodies in Europe, 2021", pages = "114825", volume = "322", doi = "10.1016/j.jviromet.2023.114825" }
Mögling, R., Reimerink, J., Stanoeva, K. R., Keramarou, M., Guiomar, R., Costa, I., Haveri, A., Holzer, B., Korukluoğlu, G., Nguyen, T., Pakarna, G., Pancer, K., Trilar, K. P., Protić, J., Stojanović, M., De Santis, R., Lista, F., Vremera, T., Leustean, M., Pistol, A., Zelena, H., Reusken, C.,& Broberg, E. K.. (2023). Comparative study between virus neutralisation testing and other serological methods detecting anti-SARS-CoV-2 antibodies in Europe, 2021. in Journal of Virological Methods Elsevier., 322, 114825. https://doi.org/10.1016/j.jviromet.2023.114825
Mögling R, Reimerink J, Stanoeva KR, Keramarou M, Guiomar R, Costa I, Haveri A, Holzer B, Korukluoğlu G, Nguyen T, Pakarna G, Pancer K, Trilar KP, Protić J, Stojanović M, De Santis R, Lista F, Vremera T, Leustean M, Pistol A, Zelena H, Reusken C, Broberg EK. Comparative study between virus neutralisation testing and other serological methods detecting anti-SARS-CoV-2 antibodies in Europe, 2021. in Journal of Virological Methods. 2023;322:114825. doi:10.1016/j.jviromet.2023.114825 .
Mögling, Ramona, Reimerink, Johan, Stanoeva, Kamelia R., Keramarou, Maria, Guiomar, Raquel, Costa, Inês, Haveri, Anu, Holzer, Barbara, Korukluoğlu, Gülay, Nguyen, Trung, Pakarna, Gatis, Pancer, Katarzyna, Trilar, Katarina Prosenc, Protić, Jelena, Stojanović, Marijana, De Santis, Riccardo, Lista, Florigio, Vremera, Teodora, Leustean, Mihaela, Pistol, Adriana, Zelena, Hana, Reusken, Chantal, Broberg, Eeva K., "Comparative study between virus neutralisation testing and other serological methods detecting anti-SARS-CoV-2 antibodies in Europe, 2021" in Journal of Virological Methods, 322 (2023):114825, https://doi.org/10.1016/j.jviromet.2023.114825 . .